Pomerleau O F, Pomerleau C S, Morrell E M, Lowenbergh J M
Department of Psychiatry, University of Michigan, Ann Arbor 48105.
Psychoneuroendocrinology. 1991;16(5):433-40. doi: 10.1016/0306-4530(91)90008-h.
The effect of fluoxetine hydrochloride, a 5-HT uptake inhibitor (60 mg/day PO), in preventing weight gain associated with nicotine reduction was investigated in participants in a double-blind, placebo-controlled smoking-cessation trial. A lunch of cheese pizza and chocolate bars was offered, and caloric intake was monitored. The analysis focused on subjects (placebo: n = 11; fluoxetine: n = 10) who succeeded in reaching cotinine levels of less than 50% of their starting cotinine levels (signifying a stringent reduction in nicotine intake) and who participated in pre- and post-nicotine reduction lunch sessions 70 days apart. Subjects on placebo gained significantly more weight (mean +/- SEM = +3.3 +/- 0.7 kg) than subjects on fluoxetine (-0.6 +/- 1.2 kg). In fluoxetine-treated subjects, weight gain/loss was strongly correlated with initial body mass index, with higher BMI being associated with greater decreases in weight. A trend towards decreased caloric intake in the fluoxetine group was observed; the change in total calories at lunch was significantly correlated with weight change, an association accounted for principally by change in pizza intake. We conclude that fluoxetine treatment effectively prevents the weight gain that accompanies nicotine reduction and that this phenomenon is mediated, at least in part, by diminished caloric intake.
在一项双盲、安慰剂对照的戒烟试验中，研究了5-羟色胺摄取抑制剂盐酸氟西汀（每日口服60毫克）对预防与减少尼古丁相关的体重增加的作用。提供了一份奶酪披萨和巧克力棒的午餐，并监测热量摄入。分析集中于那些成功使可替宁水平降至起始可替宁水平的50%以下（表明尼古丁摄入量大幅减少）且相隔70天参加了减少尼古丁摄入前后午餐环节的受试者（安慰剂组：n = 11；氟西汀组：n = 10）。服用安慰剂的受试者体重增加显著多于服用氟西汀的受试者（平均±标准误= +3.3±0.7千克 比 -0.6±1.2千克）。在接受氟西汀治疗的受试者中，体重增加/减轻与初始体重指数密切相关，较高的体重指数与更大的体重减轻相关。观察到氟西汀组有热量摄入减少的趋势；午餐时总热量的变化与体重变化显著相关，这种关联主要由披萨摄入量的变化所致。我们得出结论，氟西汀治疗可有效预防与减少尼古丁相关的体重增加，且这一现象至少部分是由热量摄入减少介导的。
